NASDAQ : FULC
Fulcrum Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.77 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 287.64M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 283.06M |
| Enterprise Value | -30.50M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 76.30M |
| Shares Outstanding | 76.30M |
| Shares Change (YoY) | +12.92% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | 88.95% |
| Float | 63.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 31.35 |
| Quick Ratio | 31.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -32.38% |
| Return on Assets (ROA) | -19.59% |
| Return on Invested Capital (ROIC) | -20.13% |
| Return on Capital Employed (ROCE) | -27.62% |
| Weighted Average Cost of Capital (WACC) | 18.35% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$9.44M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.63 |
| 52-Week Price Change | -60.36% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 5.86 |
| Relative Strength Index (RSI) | 48.81 |
| Average Volume (20 Days) | 1,405,868 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.76M |
| Short Previous Month | 7.11M |
| Short % of Shares Out | 8.86% |
| Short % of Float | 10.64% |
| Short Ratio (days to cover) | 4.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -56.10M |
| Operating Income | -86.64M |
| Pretax Income | -85.00M |
| Net Income | -85.00M |
| EBITDA | -85.40M |
| EBIT | -86.64M |
| Earnings Per Share (EPS) | -$1.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 318.84M |
| Total Debt | 5.28M |
| Net Cash | 313.56M |
| Net Cash Per Share | $4.11 |
| Equity (Book Value) | 310.70M |
| Book Value Per Share | 4.07 |
| Working Capital | 312.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -65.78M |
| Capital Expenditures | -365,000 |
| Depreciation & Amortization | 1.25M |
| Net Borrowing | n/a |
| Free Cash Flow | -66.14M |
| FCF Per Share | -$0.87 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.92% |
| Shareholder Yield | -12.92% |
| Earnings Yield | -32.63% |
| FCF Yield | -23.37% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.67 |
| Price Target Difference | -1.16% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |